Tag: Ustekinumab

According to the National Institutes of Health, ustekinumab is a human monoclonal antibody belonging to the class of interleukin inhibitors. This advanced biologic medication, commonly known as Stelara, targets specific proteins in the immune system to treat a variety of inflammatory and autoimmune diseases.

Approximately 8% of the U.S. population lives with an autoimmune disease, many of which are treated with biologic drugs. When considering treatment options, it's important to understand questions like: how is Stelara different than Humira? Both are effective biologics, but they function in fundamentally different ways.

Over 60% of patients taking some of the latest biologic medications are expected to see a complete clearance of psoriasis plaques within three to four months [1.2.6]. Understanding **how quickly do biologics work for psoriasis** involves looking at the specific drug, its mechanism, and individual patient factors.

The biologic medication ustekinumab, known by the brand name Stelara, is an interleukin antagonist used to treat various inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. A key aspect of its therapy is the administration method, which often includes subcutaneous injections for maintenance and sometimes for initial treatment. Understanding when and how ustekinumab is administered is vital for patients and healthcare providers alike.

According to the FDA, Wezlana (ustekinumab-auub) was approved on October 31, 2023, as the first interchangeable biosimilar to Stelara, meaning it is highly similar. In Europe, a similar ustekinumab biosimilar is authorized under the name Wezenla. This biologic medication, containing the active ingredient ustekinumab, treats inflammatory diseases by targeting specific proteins in the immune system.